Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients

Curtis E. Haas, Jamie L. Nelsen, Krishnan Raghavendran, William Mihalko, Joseph Beres, Qing Ma, Alan Forrest, K. Dean Grubler

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: Enoxaparin is the only low molecular-weight heparin (LMWH) with documented efficacy for the prevention of venous thromboemobolism (VTE) following trauma, and it is currently considered the treatment of choice. Recent reports have suggested that the pharmacokinetics (PK) and pharmacodynamics of LMWH products may be altered in critically ill patients. Methods: Two cohorts of critically ill multiple trauma patients were enrolled in this study: A (nonedematous) and B (edematous, defined as the presence of peripheral edema and an increase in body weight of ≥10 kg). All patients received at least four doses of enoxaparin 30 mg subcutaneously every 12 hours before the study dose. Blood samples were collected before and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours following a morning dose. Plasma anti-Xa and antithrombin (AT) activities were determined using chromogenic assays. A compartmental PK analysis model was defined for the data. PK parameters for the two cohorts were compared using a Mann-Whitney Rank Sum test. Results: The area under the curve (AUC)0-12 hour, maximal plasma anti-activated Factor Xa (anti-Xa) activity (Amax), and AT activity were significantly lower in the edematous trauma patients (p < 0.05). The AUC0-12 hour for plasma anti-Xa activity was highly variable in both study cohorts. Seven of the 10 edematous patients had barely quantifiable anti-Xa results. Activity levels were too low to reliably estimate the PK parameters for most patients in cohort B. Conclusion: The standard dose of enoxaparin recommended for the prevention of VTE following multiple trauma provides unreliable and highly variable anti-Xa activity in critically ill trauma patients, and is strongly affected by the presence of significant peripheral edema.

Original languageEnglish (US)
Pages (from-to)1336-1344
Number of pages9
JournalJournal of Trauma - Injury, Infection and Critical Care
Volume59
Issue number6
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Enoxaparin
Multiple Trauma
Factor Xa
Pharmacokinetics
Critical Illness
Antithrombins
Low Molecular Weight Heparin
Edema
Wounds and Injuries
Nonparametric Statistics
Area Under Curve
Cohort Studies
Body Weight

All Science Journal Classification (ASJC) codes

  • Surgery
  • Critical Care and Intensive Care Medicine

Cite this

Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. / Haas, Curtis E.; Nelsen, Jamie L.; Raghavendran, Krishnan; Mihalko, William; Beres, Joseph; Ma, Qing; Forrest, Alan; Grubler, K. Dean.

In: Journal of Trauma - Injury, Infection and Critical Care, Vol. 59, No. 6, 01.01.2005, p. 1336-1344.

Research output: Contribution to journalArticle

Haas, Curtis E. ; Nelsen, Jamie L. ; Raghavendran, Krishnan ; Mihalko, William ; Beres, Joseph ; Ma, Qing ; Forrest, Alan ; Grubler, K. Dean. / Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. In: Journal of Trauma - Injury, Infection and Critical Care. 2005 ; Vol. 59, No. 6. pp. 1336-1344.
@article{17b9d871ca284e1b8a619e93c39c54a3,
title = "Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients",
abstract = "Background: Enoxaparin is the only low molecular-weight heparin (LMWH) with documented efficacy for the prevention of venous thromboemobolism (VTE) following trauma, and it is currently considered the treatment of choice. Recent reports have suggested that the pharmacokinetics (PK) and pharmacodynamics of LMWH products may be altered in critically ill patients. Methods: Two cohorts of critically ill multiple trauma patients were enrolled in this study: A (nonedematous) and B (edematous, defined as the presence of peripheral edema and an increase in body weight of ≥10 kg). All patients received at least four doses of enoxaparin 30 mg subcutaneously every 12 hours before the study dose. Blood samples were collected before and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours following a morning dose. Plasma anti-Xa and antithrombin (AT) activities were determined using chromogenic assays. A compartmental PK analysis model was defined for the data. PK parameters for the two cohorts were compared using a Mann-Whitney Rank Sum test. Results: The area under the curve (AUC)0-12 hour, maximal plasma anti-activated Factor Xa (anti-Xa) activity (Amax), and AT activity were significantly lower in the edematous trauma patients (p < 0.05). The AUC0-12 hour for plasma anti-Xa activity was highly variable in both study cohorts. Seven of the 10 edematous patients had barely quantifiable anti-Xa results. Activity levels were too low to reliably estimate the PK parameters for most patients in cohort B. Conclusion: The standard dose of enoxaparin recommended for the prevention of VTE following multiple trauma provides unreliable and highly variable anti-Xa activity in critically ill trauma patients, and is strongly affected by the presence of significant peripheral edema.",
author = "Haas, {Curtis E.} and Nelsen, {Jamie L.} and Krishnan Raghavendran and William Mihalko and Joseph Beres and Qing Ma and Alan Forrest and Grubler, {K. Dean}",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.ta.0000197354.69796.bd",
language = "English (US)",
volume = "59",
pages = "1336--1344",
journal = "Journal of Trauma and Acute Care Surgery",
issn = "2163-0755",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients

AU - Haas, Curtis E.

AU - Nelsen, Jamie L.

AU - Raghavendran, Krishnan

AU - Mihalko, William

AU - Beres, Joseph

AU - Ma, Qing

AU - Forrest, Alan

AU - Grubler, K. Dean

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: Enoxaparin is the only low molecular-weight heparin (LMWH) with documented efficacy for the prevention of venous thromboemobolism (VTE) following trauma, and it is currently considered the treatment of choice. Recent reports have suggested that the pharmacokinetics (PK) and pharmacodynamics of LMWH products may be altered in critically ill patients. Methods: Two cohorts of critically ill multiple trauma patients were enrolled in this study: A (nonedematous) and B (edematous, defined as the presence of peripheral edema and an increase in body weight of ≥10 kg). All patients received at least four doses of enoxaparin 30 mg subcutaneously every 12 hours before the study dose. Blood samples were collected before and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours following a morning dose. Plasma anti-Xa and antithrombin (AT) activities were determined using chromogenic assays. A compartmental PK analysis model was defined for the data. PK parameters for the two cohorts were compared using a Mann-Whitney Rank Sum test. Results: The area under the curve (AUC)0-12 hour, maximal plasma anti-activated Factor Xa (anti-Xa) activity (Amax), and AT activity were significantly lower in the edematous trauma patients (p < 0.05). The AUC0-12 hour for plasma anti-Xa activity was highly variable in both study cohorts. Seven of the 10 edematous patients had barely quantifiable anti-Xa results. Activity levels were too low to reliably estimate the PK parameters for most patients in cohort B. Conclusion: The standard dose of enoxaparin recommended for the prevention of VTE following multiple trauma provides unreliable and highly variable anti-Xa activity in critically ill trauma patients, and is strongly affected by the presence of significant peripheral edema.

AB - Background: Enoxaparin is the only low molecular-weight heparin (LMWH) with documented efficacy for the prevention of venous thromboemobolism (VTE) following trauma, and it is currently considered the treatment of choice. Recent reports have suggested that the pharmacokinetics (PK) and pharmacodynamics of LMWH products may be altered in critically ill patients. Methods: Two cohorts of critically ill multiple trauma patients were enrolled in this study: A (nonedematous) and B (edematous, defined as the presence of peripheral edema and an increase in body weight of ≥10 kg). All patients received at least four doses of enoxaparin 30 mg subcutaneously every 12 hours before the study dose. Blood samples were collected before and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours following a morning dose. Plasma anti-Xa and antithrombin (AT) activities were determined using chromogenic assays. A compartmental PK analysis model was defined for the data. PK parameters for the two cohorts were compared using a Mann-Whitney Rank Sum test. Results: The area under the curve (AUC)0-12 hour, maximal plasma anti-activated Factor Xa (anti-Xa) activity (Amax), and AT activity were significantly lower in the edematous trauma patients (p < 0.05). The AUC0-12 hour for plasma anti-Xa activity was highly variable in both study cohorts. Seven of the 10 edematous patients had barely quantifiable anti-Xa results. Activity levels were too low to reliably estimate the PK parameters for most patients in cohort B. Conclusion: The standard dose of enoxaparin recommended for the prevention of VTE following multiple trauma provides unreliable and highly variable anti-Xa activity in critically ill trauma patients, and is strongly affected by the presence of significant peripheral edema.

UR - http://www.scopus.com/inward/record.url?scp=33646174432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646174432&partnerID=8YFLogxK

U2 - 10.1097/01.ta.0000197354.69796.bd

DO - 10.1097/01.ta.0000197354.69796.bd

M3 - Article

VL - 59

SP - 1336

EP - 1344

JO - Journal of Trauma and Acute Care Surgery

JF - Journal of Trauma and Acute Care Surgery

SN - 2163-0755

IS - 6

ER -